Yantai biomedical industry strives to break through 100 billion yuan and become a new driving force for economic growth

[industry trends of pharmaceutical network] 83.3 billion yuan, which is the total revenue of Yantai's biomedical industry in 2018 It is understood that the biomedical industry is a strategic emerging industry of Yantai It is expected that by the end of 2019, the biomedical industry of Yantai will achieve a sales revenue of 90 billion yuan, strive to break through 100 billion yuan, and become a new driving force for Yantai's economic growth As a national strategic emerging industry, biomedical and health industry is called "the sunrise industry that will never decline" Now the sun is rising slowly on the sea of Yantai According to statistics, in the first half of this year, the sales revenue of medical and health industry enterprises in the city reached 9.279 billion yuan, an increase of 6.67% year on year 36 key projects of biomedical industry are included in the "triple" work of the city, with a total planned investment of 12.3 billion yuan After all projects are put into operation, it is expected to increase revenue by 22.6 billion yuan, forming a project layout centered on the central urban area and coordinated development of the East and West wings By the end of July this year, 10 major projects have been completed and 10 new projects have been started Within this year, the target of "14 major projects have been completed and 6 new projects have been started" will be over fulfilled Three 10 billion level industrial parks are being formed, among which, the total investment of green leaf Pharmaceutical Industrial Park is 6 billion yuan, and the annual sales revenue can exceed 20 billion yuan after completion; the investment of stone pharmaceutical bio Pharmaceutical Industrial Park is 3 billion yuan, and six tumor treatment drugs are planned to be settled in the near future, which will become a large industrial cluster base of stone Pharmaceutical Group in China besides its headquarters; after the completion of phase III project of Rongchang bio pharmaceutical Park The production capacity of antibody drugs and ADC drugs can be more than 1 million, and the output value can reach 10 billion yuan The overall rise of key projects has become a strong engine to promote the development of the industry The author also learned that on September 3, the signing ceremony of the cooperation between Dongcheng pharmaceutical company, located in Yantai area of the pilot Free Trade Zone, and the project of breathid HP (breath detection of Helicobacter pylori in the stomach) of Arens biotechnology company in Israel and the project of HP detection & particle center jointly built with Shanghai Pharmaceutical Holding Co., Ltd was held in the development zone This is another project welcomed by Yantai area after the first 21 projects of Yantai area of Shandong pilot free trade zone are settled in At present, Yantai has a total of 100 biomedical Enterprises above Designated Size, 13 of which are listed in the domestic and foreign capital markets The pillar enterprises represented by LVYE pharmaceutical, Dongcheng pharmaceutical, Ruikang pharmaceutical and Rongchang pharmaceutical have developed steadily, and their position in the industry has been continuously improved; Emerging companies such as petrochemicals Parke, norcon pharmaceutical, and mabury have grown rapidly and become key enterprises in the subdivision field According to the industry, Yantai's biomedical and health industry has entered a golden age of rapid development It is understood that in order to encourage the innovation and development of biomedical industry, Yantai city continues to increase policy support, with major projects as the carrier, scientific and technological innovation as the driving force and platform as the support, and explore the use of capital power to promote the sustainable, high-quality and healthy development of the industry At the same time, Yantai is also actively building a number of high-level innovation platforms to attract more talents Recently, it was revealed at the promotion meeting of key projects of medical and health industry in Yantai that there are 4 national comprehensive new drug R & D technology platform demonstration enterprises, 1 National Key Laboratory, 1 National Engineering Laboratory, 1 foreign academician workstation, 1 national certified enterprise technology center, 2 postdoctoral mobile stations, 3 provincial enterprise technology centers and 3 provincial engineering technology research centers in Yantai 7 hearts   Next, Yantai area will take biopharmaceuticals and chemicals as the basis, in vitro diagnosis, implant access, medical materials and health care products as the focus, research and development of therapeutic vaccines, gene therapy, cell therapy and other new products as the breakthrough, adhere to the combination of independent innovation and the introduction of advanced technology, and focus on the realization of the original innovation of major disease control drugs and biological products By 2024, we will strive to break through 20 billion yuan in the scale of biomedical industry cluster and build a "northern Medicine Valley" with national influence "Yantai's biopharmaceutical environment is quite good, ranking relatively high, and large pharmaceutical factories such as Rongchang and LVYE have certain status and influence in China." When it comes to the environment of Yantai's biomedical and health industry, relevant people said that Yantai has developed rapidly in recent years For enterprises, the industrial environment and government policy support are very good.